Polaryx Therapeutics, Inc.

PLYX · Nasdaq · SIC 2834: Pharmaceutical Preparations
4
SEC Filings

Business Summary

Polaryx Therapeutics is a clinical-stage biotechnology company developing novel disease-modifying therapies for rare, pediatric lysosomal storage diseases (LSDs). Its pipeline includes PLX-200 (gemfibrozil, oral small molecule), PLX-300 (cinnamic acid), PLX-100 (combination therapy), and PLX-400 (gene therapy). Lead candidate PLX-200 is advancing through a Phase 2 basket trial (SOTERIA) targeting CLN2, CLN3, Krabbe disease, and Sandhoff disease, with an FDA-cleared IND received in October 2025.

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionPLYXdiscussed_in_filing Artificial Intelligence
topic_mentionPLYXdiscussed_in_filing Cybersecurity
topic_mentionPLYXdiscussed_in_filing Trusted Computing
topic_mentionPLYXdiscussed_in_filing Blockchain & Crypto
topic_mentionPLYXdiscussed_in_filing Capital Expenditure
topic_mentionPLYXdiscussed_in_filing Regulation
topic_mentionPLYXdiscussed_in_filing Healthcare & Bio
topic_mentionPLYXdiscussed_in_filing Artificial Intelligence
topic_mentionPLYXdiscussed_in_filing Cybersecurity
topic_mentionPLYXdiscussed_in_filing Trusted Computing
topic_mentionPLYXdiscussed_in_filing Blockchain & Crypto
topic_mentionPLYXdiscussed_in_filing Capital Expenditure
topic_mentionPLYXdiscussed_in_filing Regulation
topic_mentionPLYXdiscussed_in_filing Healthcare & Bio
topic_mentionPLYXdiscussed_in_filing Artificial Intelligence
topic_mentionPLYXdiscussed_in_filing Cybersecurity
topic_mentionPLYXdiscussed_in_filing Trusted Computing
topic_mentionPLYXdiscussed_in_filing Blockchain & Crypto
topic_mentionPLYXdiscussed_in_filing Capital Expenditure
topic_mentionPLYXdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-242025-12-310001213900-26-033064EDGAR102K words

Quarterly Reports (10-Q)

No 10-Q filings indexed.

4 total filings indexed. 3 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

rare-pediatric-lysosomal-storage-diseases-(lsds) neuronal-ceroid-lipofuscinoses-(ncls) krabbe-disease gm2-gangliosidoses-(tay-sachs-and-sandhoff-diseases) niemann-pick-disease-types-a-and-b orphan/rare-disease-therapeutics 505(b)(2)-regulatory-pathway ppar-dependent-upregulation-of-tfeb lysosomal-biogenesis-via-tfeb-activation pi3k-pathway-activation

Company Identity

CIK0002075320
TickerPLYX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedWY

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 3c661bc83c478a2ad811107b57dd21f64db345da690f17a6b32f94596f03ab32
parent: e5e4b7f4e395b3c4164edf8b089be7b8383d72d069b4ed0543c57da74d68d568
content hash: 40bec8cc7fa8c0b68f8a9bc562c2b4720abf7e41c9726065cb1d7e41d0cc41cc
signed: 2026-04-13T04:46:56.328Z
sources: 1 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf